A complete sample Trial Options Report
This is what the workbench generates in minutes, branded to the advocate's own practice. Fictional patient, real ClinicalTrials.gov data.
58-year-old, stage IV colorectal adenocarcinoma. Liver and lung metastases. MSS (pMMR), KRAS G12D, BRAF wild-type, HER2 negative. Two prior lines: FOLFOX + bevacizumab, then FOLFIRI + bevacizumab, progressed on both. ECOG 1, no brain metastases, adequate organ function.
Why: Stage IV colorectal cancer with a KRAS G12D mutation, ECOG 1, and two prior lines meets every key inclusion criterion for this KRAS G12D-targeted therapy trial.
- KRAS G12D mutation confirmed in the profile, matching the trial's specific molecular target
- Metastatic (stage IV) colorectal cancer with measurable disease meets the advanced solid tumor requirement
- ECOG performance status of 1 meets the ≤1 requirement
- Two prior lines of systemic therapy satisfy the ≥1 prior-line requirement
- No exclusionary criteria noted in the profile (no active CNS metastases or other active malignancy)
- Confirm KRAS G12D is documented in the NGS report (tumor tissue or ctDNA)
- Verify prior-therapy toxicities have resolved to Grade 1 or less
- Confirm hepatitis B and C status are negative or inactive
Why: KRAS G12D-mutant metastatic colorectal cancer with adequate prior therapy and ECOG 1 fits the eligible dose-escalation cohort.
- KRAS G12D is specifically listed as eligible for the dose-escalation cohorts
- Advanced/metastatic colorectal cancer is a solid tumor appropriate for this trial
- ECOG 1 meets the required 0 or 1 performance status
- Two prior lines of standard therapy satisfy the prior-therapy requirement
- Confirm KRAS G12D is documented in a DNA sequencing report (not inferred)
- Verify adequate organ function per protocol-specific lab criteria
- Confirm no active brain metastases or CNS involvement
Why: The patient meets the clinical criteria, but the trial requires self-identification as a Black/African American or Hispanic/Latino minority population — confirm before proceeding.
| NCT07018869 | Survivorship study; stage II/III only, stage IV explicitly excluded |
| NCT07140679 | Requires dMMR/MSI-H after curative surgery; patient is MSS, stage IV |
| NCT05253651 | Requires HER2-positive and RAS wild-type; patient is HER2-negative, KRAS G12D |
| NCT06750094 | Requires KRAS/NRAS/BRAF wild-type; also excludes prior irinotecan |
| NCT07221357 | First-line only; patient has had two lines |
| NCT06205485 | Non-metastatic rectal cancer, treatment-naive |
| NCT05080673 | Polyp surveillance; prior colorectal cancer excluded |
| NCT07283939 | Must be in cycle 1 of first-line FOLFOX right now |
| NCT06662786 | First-line, RAS wild-type required |
| NCT07112690 | Different disease (anal cancer study) |
| NCT05108298 | Age 18-39 required (adolescent/young-adult study) |
| NCT07284849 | MSS fits, but first-line only |
| NCT06377852 | Excludes prior CDK4/6 inhibitor for metastatic disease |
Sites finish enrolling, pause, or lose an investigator long before the listing changes. Every strong-candidate site gets a verification call before the patient's oncologist is asked to spend time on it — that is why this report separates what the registry claims from what a phone call confirmed.
This is the deliverable founding members produce in minutes, under their own practice name. If you build reports like this by hand today, I want to talk to you.